Recent regulatory shifts have critical implications for how biosimilar developers generate and prioritise information. Read ICON’s latest article in PharmTech Magazine, to learn what these changes mean for data collect...
- Home
- News & Events
- In the News
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Engaging the crowds
A thought leadership piece by Peter Schueler which considers the importance of patient engagement and enrollment in Alzheimer's clinical trials.
This article is taken from International Clinical Trials November 2020, pages 10-12. © Samedan Ltd.
-
Data capture in a post-digital clinical trial landscape
A thought leadership article authored by Tom O’Leary on how collected data from digital health technologies, coupled with novel clinical trial models, have the ability to increase the value proposition of drugs and medical devices.
This article is taken from Innovations in Pharmaceutical Technology Autumn/Winter 2020, pages 38-40. © Samedan Ltd
-
The quest for increased efficiency in personalised medicine clinical trials
A thought leadership piece by Lawrence Johnson and Cynthia Spittle discussing personalised medicine and how digital devices can improve treatment across a wide spectrum of conditions (pages 16-17).
-
BARDA reselects ICON as preferred partner
An article focused on the BARDA announcement that ICON continues to be a part of The Clinical Trials Planning and Execution component of the CSN, responsible for planning and executing clinical studies to support medical countermeasure development.
-
AI in Life Sciences – Covid pushes AI driven clinical trials and drug manufacturing into the limelight
ICON’s CIO, Tom Leary discusses the challenges to patient recruitment during the COVID pandemic and how big data, combined with advanced AI algorithms processing has the potential to reduce trial costs.
-
Navigating cell therapy manufacturing amid pandemic woes
An article featuring expert commentary from ICON's Tamie Joeckel on supply-chain strategies to help mitigate vulnerabilities in both autologous and allogeneic cell therapy manufacturing.
-
Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan
This published study conducted by ICON's Health Economics team and Bristol-Myers Squibb evaluates a cost-effective new treatment for melanoma patients in Japan.
-
The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies
ICON's Richard Pitman joins global public health experts to address the importance of flu vaccination programs amid the COVID-19 pandemic.
-
How to measure your patient-centric impact
A patient insight article on the benefit of patient centric clinical trial design.
-
Developing enhanced digital content to increase physician engagement
With in-person scientific congresses an impossibility for the foreseeable future, researchers and publishers have to adapt how they foster scientific exchange. Experts from ICON's Medical Communications team discuss how they are using enhanced media fit for the digital age.